Related Experiment Video
Updated: Jun 6, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency
L Tabatabaie1, L W J Klomp, M E Rubio-Gozalbo
1Department of Metabolic and Endocrine Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.
Unlabelled:
3-Phosphoglycerate dehydrogenase (3-PGDH) deficiency is considered to be a rare cause of congenital microcephaly, infantile onset of intractable seizures and severe psychomotor retardation. Here, we report for the first time a very mild form of genetically confirmed 3-PGDH deficiency in two siblings with juvenile onset of absence seizures and mild developmental delay. Amino acid analysis showed serine values in CSF and plasma identical to what is observed in the severe infantile form. Both patients responded favourably to relatively low dosages of serine supplementation with cessation of seizures, normalisation of their EEG abnormalities and improvement of well-being and behaviour. These cases illustrate that 3-PGDH deficiency can present with mild symptoms and should be considered as a treatable disorder in the differential diagnosis of mild developmental delay and seizures.
Synopsis:
we present a novel mild phenotype in patients with 3-PGDH deficiency.
Related Concept Videos
Other Glycolytic Pathways
Lysosomal Hydrolases
Pharmacogenomics: Identification of New Drug Targets
Inborn Errors of Metabolism
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis —consists of two...

